Entrada Therapeutics, Inc. Stock Price, News & Analysis

Entrada Therapeutics (Nasdaq: TRDA) reported clinical and preclinical progress across its RNA-based neuromuscular and ocular programs and confirmed cash to fund operations into Q3 2027. Key near-term milestones include planned data readouts from the first cohorts of ELEVATE-44-201 in Q2 2026 and ELEVATE-45-201 in mid-2026, initiation of a Phase 1/2 MAD study of ENTR-601-50 by end-2026, and global regulatory submissions for ENTR-601-51 in 2026. Entrada also nominated ENTR-801 as its first ocular clinical candidate for Usher syndrome type 2A and expects a second ocular candidate in 2026. The company will present at the J.P. Morgan Healthcare Conference on Jan 14, 2026.

Entrada Therapeutics (Nasdaq: TRDA) will present at the 44th Annual J.P. Morgan Healthcare Conference. Dipal Doshi, CEO, will deliver the company presentation on Wednesday, January 14, 2026 at 3:45 PM PT (6:45 PM ET). A live webcast will be available on Entrada’s Investor Relations site and will be archived for 30 days after the event.

Entrada Therapeutics (Nasdaq: TRDA) granted an aggregate of 40,650 RSUs and options to purchase 38,850 shares to five newly hired non-executive employees under its 2025 Inducement Equity Plan, effective Dec 1, 2025. The options have an exercise price of $9.91, equal to the closing price on Dec 1, 2025. Grants were approved by the Compensation Committee as inducements under Nasdaq Listing Rule 5635(c)(4).

Vesting: options vest 25% at one year then monthly over three years to full vest at four years; RSUs vest 25% at one year then 6.25% quarterly on Mar 1/Jun 1/Sep 1/Dec 1, subject to continued service. Grants are subject to the Inducement Plan and award agreements.

Entrada Therapeutics (Nasdaq: TRDA) reported Q3 2025 results and pipeline updates on Nov 6, 2025. The company reported $326.8M in cash, cash equivalents and marketable securities as of Sept 30, 2025 and expects runway into Q3 2027. Entrada is advancing multiple Duchenne muscular dystrophy programs: ELEVATE-44-201 (data from Cohort 1 expected Q2 2026), ELEVATE-45-201 (first patient dosed; Cohort 1 data mid-2026), and a regulatory filing in the U.K. to start ELEVATE-50-201 with EU filings planned H2 2026.

Q3 financials: collaboration revenue $1.6M, R&D expense $38.4M, G&A $10.3M, and net loss $(44.1)M.

Entrada Therapeutics (Nasdaq: TRDA) will present at two investor conferences in late 2025. The company said CEO Dipal Doshi will deliver a presentation at the Jefferies Global Healthcare Conference in London on November 18, 2025 at 5:00 p.m. GMT and will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami on December 3, 2025 at 12:55 p.m. ET.

Both events will be webcast live via the company’s Investor Relations website at www.entradatx.com, with replays available for 90 days after each event.

Entrada Therapeutics (Nasdaq: TRDA) has announced the recipients of its third annual DREAMS Grant Program, awarding $50,000 each to two non-profit organizations: Jett Foundation (US) and Parent Project aps (Italy). The grants aim to support underrepresented and underserved members of the Duchenne muscular dystrophy community.

Jett Foundation will utilize the funding for its Camp Promise program, targeting individuals aged 18 and older with Duchenne and other neuromuscular disorders, aiming to support over 250 campers in 2025. Parent Project aps will focus on providing home-based care and teleconsultation services to families in underserved regions of Southern Italy.

The recipients were selected by an independent grant review committee comprising neuromuscular leaders and advocates, with the announcement made ahead of World Duchenne Awareness Day on September 7.

Entrada Therapeutics (Nasdaq: TRDA) announced the granting of equity incentives to seven new non-executive employees under its 2025 Inducement Equity Plan. The grants include 54,360 restricted stock units (RSUs) and options to purchase 38,850 shares at an exercise price of $5.47 per share.

The options will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over three years. The RSUs will vest 25% after one year, followed by quarterly vesting of 6.25% on specified dates. All grants are subject to continued employment and were approved as material inducements under Nasdaq Listing Rule 5635(c)(4).

Entrada Therapeutics (Nasdaq: TRDA) reported Q2 2025 financial results and clinical progress. The company achieved significant milestones in its Duchenne muscular dystrophy (DMD) programs, with the first patient dosed in ELEVATE-44-201 and initiation of ELEVATE-45-201. Financial highlights include $354 million in cash providing runway into Q2 2027, though the company reported a net loss of $43.1 million compared to $55.0 million net income in Q2 2024.

The company strengthened its leadership team with key appointments and advanced multiple clinical programs across the UK, EU, and US. Data from the first patient cohort of ELEVATE-44-201 is expected in H1 2026, while ELEVATE-45-201 is set to dose its first patient in Q3 2025. Entrada also plans regulatory submissions for ELEVATE-50 in Q4 2025 and ELEVATE-51 in 2026.

Entrada Therapeutics (NASDAQ: TRDA) has appointed Dr. Maha Radhakrishnan to its Board of Directors. Dr. Radhakrishnan currently serves as Executive Partner at Sofinnova Investments, bringing extensive experience in global drug development. She previously held the position of Group SVP and Chief Medical Officer at Biogen and served in leadership roles at Sanofi, Bioverativ, Bristol Myers Squibb, UnitedHealth Group, and Cephalon. The appointment comes as Entrada advances its Duchenne muscular dystrophy franchise, with promising Phase 1 safety and target engagement data. The company aims to develop intracellular therapies for Duchenne and other serious diseases, with multiple patient-focused clinical trials planned throughout the year.